proliferative

Antiproliferative agent-22 is an anticancer compound that shows antiproliferative activity on MCF-7, MDA-MB-231, and MDA-MB-468 cells.Antiproliferative agent-22 is used in cancer research.

Antiproliferative agent-16 (Antiproliferative agent-16) is an indolyl hydrazide-hydrazone compound with anticancer activity. Antiproliferative agent-16 exhibits specificity toward breast cancer cells (IC50 of 6.94 μM for MCF-7 cells).

Antiproliferative agent-15 is a reagent with anticancer activity. Antiproliferative agent-15 showed antiproliferative activity against human colon cancer (HCT116 and HCT15) and brain cancer (LN-229 and GBM-10).

Antiproliferative agent-13 is a compound with antiproliferative activity.

Antiproliferative agent-7 (compound 8f) is a potent anti-proliferative agent that promotes ROS production and induces apoptosis.

Antiproliferative agent-4 showed good anti-proliferative effects on some cancer cells. antiproliferative agent-4 inhibited tumour growth in nude mice and showed low toxicity. antiproliferative agent-4 reduced the mitochondrial membrane potential of EC109 cells and increased Antiproliferative agent-4 reduced the mitochondrial membrane potential of EC109 cells and increased the apoptosis rate and ROS level.

Antiproliferative Agent-33 (Compound 2g) serves as an anti-proliferative, antifungal, and antibacterial agent, effectively inhibiting the proliferation of MDA-MB-231 cells (IC50: 16.38 μM), impairing the growth of gram-negative bacteria, and restraining S. faecalis with an MIC of 8 μg mL [1].

Antiproliferative Agent-58 (compound 8nj) is an effective antiproliferative agent that exhibits activity under both normoxic and hypoxic conditions.

Antiproliferative agent-56 (Compound 31) is an antimalarial agent that inhibits the Pf3D7 strain of the malaria parasite Plasmodium falciparum with an IC50 of >12.5 (48h) and 0.03 μM (98h), displaying slow-acting characteristics.

Antiproliferative agent-57 (compound M2) is a tumor angiogenesis inhibitor that suppresses VEGF secretion in SiHa cells under hypoxic conditions without inducing cytotoxicity (IC50=0.68 μM). It modulates the PI3K AKT mTOR and MAPK signaling pathways in tumor cells, thereby inhibiting the expression of HIF-1α and VEGF within tumor tissues.

Antiproliferative agent-60 (compound 8c), an 11-Azaartemisinin derivative, exhibits outstanding anticancer activity. It demonstrates tumor selectivity up to 32 times higher when compared to normal Hek293 cells. The IC50 values for Antiproliferative agent-60 are 7.7 μM for epidermoid carcinoma (KB), 42.5 μM for HepG2, and 15.5 μM for A549 cells.

Antiproliferative agent-59 (Compound 14u) acts as an inhibitor of tubulin polymerization. Demonstrating anticancer activity in Huh7, SGC-7901, and MCF-7 cell lines, this compound achieves IC50 values of 0.03, 0.18, and 0.13 μM, respectively. Additionally, it arrests the cell cycle at the G2 M phase and induces apoptosis in Huh7 cells. In a xenograft mouse model utilizing Huh7 cells, Antiproliferative agent-59 exhibits antitumor effects against hepatocellular carcinoma without significant toxicity.

Antiproliferative agent-63 (compound 4d) is a cyclic analog of cannabidiol that acts as an anticancer agent. It demonstrates favorable activity against breast and colorectal cancer. Moreover, this compound can arrest the cell cycle in the G1 phase and induce apoptosis through the mitochondrial pathway in breast cancer cell lines.

Antiproliferative agent-64 (Compound 76) functions as an inhibitor of the eukaryotic translation initiation factor 4E (eIF4E) and disrupts the secondary structure of mRNA, thereby hindering protein translation. It inhibits the 5' untranslated region (5'UTR) of c-Myc with an EC50 of 1.2 nM and the 5'UTR of tubulin with an EC50 of 40 nM. Additionally, Antiproliferative agent-64 suppresses the proliferation of MDA-MB-231 cells with an EC50 of 7 nM.

Antiproliferative agent-66 (Compound B3) is an antiproliferative compound that induces apoptosis and causes cell cycle arrest. It demonstrates IC50 values ranging from 2.03 to 3.6 µM against SH-SY5Y neuroblastoma, HT-29 colorectal adenocarcinoma, and fibroblasts. Additionally, Antiproliferative agent-66 functions as a microtubule polymerization inhibitor with an IC50 of 0.79 µM.

Antiproliferative agent-3 (comp 4) exhibits potent growth inhibitory effects against MCF-7 cells with an IC50 of 0.19 nM [1].

Antiproliferative agent-6 (compound 8a) is a potent antitumor compound exhibiting antiproliferative activity. It inhibits cancer cell lines HCT116, MCF-7, H460, and non-tumor aneuploid immortal keratinocyte HaCaT cells with GI50 values of 0.5 μM, 2 μM, 0.7 μM, and 3.5 μM, respectively.

Antiproliferative agent-8 (Compound 5a) is an anti-cancer compound that significantly increases P53 levels.

Antiproliferative agent-5 (compound 4o) irreversibly and significantly inhibits the proliferation of gastric cancer cells, blocks the cell cycle in the G2 M phase, induces ROS accumulation, and activates cellular autophagy. Antiproliferative agent-5 can be used in anti-cancer research.

Antiproliferative Agent-20 is a potent, orally active anticancer compound exhibiting both antiproliferative and anti-angiogenic activities.

Antiproliferative Agent-10, a ruthenium(II)-tris-pyrazolylmethane complex, functions as an anti-tumor compound by impeding cancer cell growth through the inhibition of mitochondrial calcium uptake.

Antiproliferative Agent-11, a selective Ruthenium(II)-Tris-pyrazolylmethane complex, exhibits antiproliferative effects on MCF-7, HeLa, 518A2, HCT116, and RD cancer cell lines with IC50 values of 6, 10, 6.8, 6.7, and 6 μM, respectively. This compound is utilized in cancer research.

Antiproliferative Agent-17 exhibits both antimicrobial properties against Gram-positive bacteria and anticancer activity [1].

Antiproliferative Agent-19, an anti-cancer compound, demonstrates antiproliferative effects by inducing apoptosis in lung cancer cells and causing cell cycle arrest in the G2 M phase.